• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product

Video

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Transcript

What can practices do to help manage the possibility of having to stock and manage multiple biosimilars for the same reference product?

Jensen: Unfortunately, I do not see this going away anytime soon until we have some more of that biosimilar parity legislation or more collaboration between health systems and payers on choosing preferred products. Until then, we're going to have to stock whatever biosimilars are covered by the patient's insurance in order to prevent that patient liability.

Related Videos
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
dr monica li
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.